Brookie Best

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir
    Brookie M Best
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093 0719, USA
    J Acquir Immune Defic Syndr 59:376-81. 2012
  2. pmc Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children
    Brookie M Best
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093 0719, USA
    J Acquir Immune Defic Syndr 58:385-91. 2011
  3. pmc Lopinavir tablet pharmacokinetics with an increased dose during pregnancy
    Brookie M Best
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, USA
    J Acquir Immune Defic Syndr 54:381-8. 2010
  4. pmc Low atazanavir concentrations in cerebrospinal fluid
    Brookie M Best
    Skaggs School of Pharmacy andPharmaceutical Sciences, School of Medicine, Department of Pediatrics, University of California, San Diego, 9500 Gilman Drive, MC 0719, La Jolla, CA 92093 0719, USA
    AIDS 23:83-7. 2009
  5. ncbi request reprint Tipranavir: a protease inhibitor for multi-drug resistant HIV-1
    Brookie Best
    University of California, San Diego, CA 92103 8214, USA
    Expert Opin Investig Drugs 15:59-70. 2006
  6. ncbi request reprint Efavirenz--still first-line king?
    Brookie M Best
    University of California, Division of Pharmacology and Drug Discovery, San Diego, La Jolla, CA 92093 0719, USA
    Expert Opin Drug Metab Toxicol 4:965-72. 2008
  7. ncbi request reprint Impact of pregnancy on abacavir pharmacokinetics
    Brookie M Best
    University of California San Diego, California 92103 8214, USA
    AIDS 20:553-60. 2006
  8. ncbi request reprint A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients
    Brookie M Best
    University of California, San Diego, San Diego, CA 92013, USA
    J Acquir Immune Defic Syndr 46:433-42. 2007
  9. pmc Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system
    Scott Letendre
    University of California, San Diego, 150 W Washington St, San Diego, CA 92103, USA
    Arch Neurol 65:65-70. 2008
  10. ncbi request reprint Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
    Miguel Goicoechea
    University California, School of Medicine, San Diego, CA 92103, USA
    Expert Opin Pharmacother 8:371-82. 2007

Detail Information

Publications22

  1. pmc Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir
    Brookie M Best
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093 0719, USA
    J Acquir Immune Defic Syndr 59:376-81. 2012
    ..The study's objective was to determine tenofovir's penetration into cerebrospinal fluid (CSF)...
  2. pmc Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children
    Brookie M Best
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093 0719, USA
    J Acquir Immune Defic Syndr 58:385-91. 2011
    ..In clinical practice, Kaletra tablets are occasionally crushed for pediatric administration. This study compared lopinavir/ritonavir exposure between whole and crushed tablets in HIV-infected children...
  3. pmc Lopinavir tablet pharmacokinetics with an increased dose during pregnancy
    Brookie M Best
    Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, CA, USA
    J Acquir Immune Defic Syndr 54:381-8. 2010
    ..This study determined lopinavir exposure with an increased dose of the new tablet formulation during the third trimester...
  4. pmc Low atazanavir concentrations in cerebrospinal fluid
    Brookie M Best
    Skaggs School of Pharmacy andPharmaceutical Sciences, School of Medicine, Department of Pediatrics, University of California, San Diego, 9500 Gilman Drive, MC 0719, La Jolla, CA 92093 0719, USA
    AIDS 23:83-7. 2009
    ..The objective of this study was to determine atazanavir penetration into cerebrospinal fluid (CSF)...
  5. ncbi request reprint Tipranavir: a protease inhibitor for multi-drug resistant HIV-1
    Brookie Best
    University of California, San Diego, CA 92103 8214, USA
    Expert Opin Investig Drugs 15:59-70. 2006
    ..It displays activity against the virus that is cross-resistant to other protease inhibitors. In this review, issues in treating multi-drug resistant HIV-1 and the potential clinical utility of tipranavir in the US will be discussed...
  6. ncbi request reprint Efavirenz--still first-line king?
    Brookie M Best
    University of California, Division of Pharmacology and Drug Discovery, San Diego, La Jolla, CA 92093 0719, USA
    Expert Opin Drug Metab Toxicol 4:965-72. 2008
    ..Recently, several new antiretroviral drugs, including second generation NNRTIs, protease-inhibitors, an integrase-inhibitor and a CCR5 inhibitor, have become or will be shortly available...
  7. ncbi request reprint Impact of pregnancy on abacavir pharmacokinetics
    Brookie M Best
    University of California San Diego, California 92103 8214, USA
    AIDS 20:553-60. 2006
    ..To describe abacavir pharmacokinetics during pregnancy and postpartum; physiological changes during pregnancy are known to affect antiretroviral drug disposition...
  8. ncbi request reprint A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients
    Brookie M Best
    University of California, San Diego, San Diego, CA 92013, USA
    J Acquir Immune Defic Syndr 46:433-42. 2007
    ..To improve the utility of therapeutic drug monitoring (TDM) by defining the proportion of patients with and predictors of above or below target protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) concentrations...
  9. pmc Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system
    Scott Letendre
    University of California, San Diego, 150 W Washington St, San Diego, CA 92103, USA
    Arch Neurol 65:65-70. 2008
    ..To evaluate whether penetration of a combination regimen into the central nervous system (CNS), as estimated by the CNS Penetration-Effectiveness (CPE) rank, is associated with lower cerebrospinal fluid (CSF) viral load...
  10. ncbi request reprint Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
    Miguel Goicoechea
    University California, School of Medicine, San Diego, CA 92103, USA
    Expert Opin Pharmacother 8:371-82. 2007
    ....
  11. doi request reprint Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy
    Miguel Goicoechea
    Antiviral Research Center, University of California, San Diego, 150 W Washington St, Ste 100, San Diego, CA 92103, USA
    J Infect Dis 197:102-8. 2008
    ....
  12. ncbi request reprint Reduced lopinavir exposure during pregnancy
    Alice M Stek
    Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA, USA
    AIDS 20:1931-9. 2006
    ..Pregnancy can alter antiretroviral pharmacokinetics. Our objective was to describe lopinavir/ritonavir (LPV/r) pharmacokinetics during pregnancy...
  13. pmc Lopinavir protein binding in HIV-1-infected pregnant women
    F T Aweeka
    Drug Research Unit, University of California, San Francisco, CA 94143 0622, USA
    HIV Med 11:232-8. 2010
    ..We report lopinavir (LPV) PB during third trimester (antepartum, AP) compared to > or =1.7 weeks postpartum (PP) to determine if FU changes compensate for reduced total concentrations reported previously...
  14. ncbi request reprint The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system
    Scott L Letendre
    University of California, 150 W Washington St, San Diego, CA 92103, USA
    J Neuroimmune Pharmacol 2:120-7. 2007
    ..Some of these drugs, such as serotonin reuptake inhibitors (SRIs) and HMG-CoA reductase inhibitors (statins), may do so by reducing HIV replication in the CNS and are already widely used by HIV-infected individuals...
  15. doi request reprint Lopinavir exposure with an increased dose during pregnancy
    Mark Mirochnick
    Department of Pediatrics, Boston University School of Medicine, and Infectious Disease Division, Children s Hospital Boston, Boston, MA 02118, USA
    J Acquir Immune Defic Syndr 49:485-91. 2008
    ..The goal of this study was to determine LPV exposure during the third trimester of pregnancy and 2 weeks postpartum with a higher LPV/RTV dose...
  16. pmc Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1
    David Croteau
    HIV Neurobehavioral Research Center, University of California San Diego, 220 Dickinson, Suite B, 8208, San Diego, CA 92103, USA
    Antimicrob Agents Chemother 54:5156-60. 2010
    ..As a component of effective antiretroviral regimens or as the main antiretroviral, RAL likely contributes to the control of HIV replication in the nervous system...
  17. ncbi request reprint Enhancing an introductory Pharmacy Practice Experience at free medical clinics
    Candis M Morello
    University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla 92093 0719, USA
    Int J Pharm Pract 18:51-7. 2010
    ..The aim of the study was to assess and improve first-year student pharmacists' satisfaction and learning experience in a Student-Run Free Medical Clinic Project (SFMCP) providing medical care to an underserved population...
  18. ncbi request reprint Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries
    Jan D Hirsch
    University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, 9500 Gilman Drive, Mail Code 0714, La Jolla, CA 92093 0714, USA
    J Manag Care Pharm 15:32-41. 2009
    ..In January 2005, a pilot program to evaluate MTM services for patients with HIV/AIDS began in California, allowing 10 HIV/AIDS specialty pharmacies to receive compensation for the MTM services that they provided to HIV/AIDS patients...
  19. doi request reprint Development of an ambulatory palliative care pharmacist practice
    Rabia Samady Atayee
    Doris A Howell Palliative Care ServiceUniversity of California, San DiegoSkaggs School of Pharmacy and Pharmaceutical Sciences, Jolla, CA 92093 0845, USA
    J Palliat Med 11:1077-82. 2008
    ..Our objective was to establish a model for incorporating an outpatient clinical pharmacist as part of a multidisciplinary palliative care team...
  20. ncbi request reprint Failure of modified directly observed therapy combined with therapeutic drug monitoring to enhance antiretroviral adherence in a patient with major depression
    Miguel Goicoechea
    University California San Diego, School of Medicine, San Diego, California 92103, USA
    AIDS Patient Care STDS 20:233-7. 2006
    ..It should be recognized that not all patients are capable of achieving lifelong medication adherence and may benefit from continued supervised therapy...
  21. pmc Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease
    Jane C Burns
    Department of Pediatrics, University of California San Diego School of Medicine and Rady Children s Hospital San Diego, La Jolla, CA, USA
    J Pediatr 153:833-8. 2008
    ..To investigate the safety, tolerability, and pharmacokinetics of the anti-tumor necrosis factor-alpha monoclonal antibody infliximab in subjects with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD)...